The mission of the Penn ADCC is to increase research and education on AD, related dementias, normal brain aging and mild cognitive impairment (MCI), as well as support development of better diagnostics and preventions/treatments for AD and related disorders. The Penn ADCC provides research training, stimulates new research on normal aging and neurodegenerative dementias as well as development of novel techniques to address the challenges of conducting research on these disorders. The Penn ADCC is a highly interdisciplinary and seamlessly integrated Center with 5 Cores that collaborate extensively with other investigators at and beyond Penn, including the NIH/NIA funded AD Centers (ADCs), NACC, AD Cooperative Study (ADCS), AD Education and Referral (ADEAR) Center, the AD Neuroimaging Initiative (ADNI), AD Genetics Consortium (ADGC) and other NIH/public/private initiatives on AD, related disorders and healthy brain aging.
The Aims of the Penn ADCC are implemented through: 1) Administrative Core A to oversee and direct the activities of the ADCC;2) Clinical Core B to recruit, follow and study subjects with AD, MCI or related disorders and controls;3) Data Management and Biostatistics Core C to provide data management and biostatistical expertise;4) Neuropathology, Genetics and Biomarker Core D to establish postmortem diagnoses on ADCC subjects, and bank CNS tissues, DNA and biofluids from ADCC subjects for diagnostic studies and research;5) Education, Recruitment and Retention Core E to develop, implement and monitor recruitment and retention programs and ensure that the ADCC team as well as patients and families have up to- date knowledge of AD and related diseases;6) Pilot Grant Program to stimulate novel research on AD and related disorders;7) Collaborations with other investigators at and beyond Penn to improve diagnostics and treatments for AD and related disorders as well as increase understanding of these conditions and promote healthy brain aging. In summary, the Penn ADCC contributes to US and global strategies to meet the worldwide challenges of rapidly aging populations and the epidemic of AD and related disorders. In alignment with NIA RFA-AG-11- 005, the Penn ADCC accomplishes its mission in the renewal period through research on AD and related disorders as well as normal aging and through education to increase understanding of these disorders and their global effects.
of the Penn ADCC is that it challenges/re-defines current clinical practice paradigms and research on AD and related disorders as well as MCI and normal aging by utilizing novel concepts and approaches to achieve the goals of this ADCC which are to increase research and education on AD, related dementias, normal brain aging and MCI, as well as support development of better diagnostics and preventions/treatments for AD and related disorders.
|LoBue, Christian; Wadsworth, Hannah; Wilmoth, Kristin et al. (2017) Traumatic brain injury history is associated with earlier age of onset of Alzheimer disease. Clin Neuropsychol 31:85-98|
|Cousins, Katheryn A Q; Ash, Sharon; Irwin, David J et al. (2017) Dissociable substrates underlie the production of abstract and concrete nouns. Brain Lang 165:45-54|
|Henderson, Michael X; Chung, Charlotte Hiu-Yan; Riddle, Dawn M et al. (2017) Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies. J Neurosci 37:5870-5884|
|Bell, S P; Liu, D; Samuels, L R et al. (2017) Late-Life Body Mass Index, Rapid Weight Loss, Apolipoprotein E ?4 and the Risk of Cognitive Decline and Incident Dementia. J Nutr Health Aging 21:1259-1267|
|Phillips, Jeffrey S; Da Re, Fulvio; Dratch, Laynie et al. (2017) Neocortical origin and progression of gray matter atrophy in nonamnestic Alzheimer's disease. Neurobiol Aging 63:75-87|
|Brown, Christopher A; Johnson, Nathan F; Anderson-Mooney, Amelia J et al. (2017) Development, validation and application of a new fornix template for studies of aging and preclinical Alzheimer's disease. Neuroimage Clin 13:106-115|
|Chapuis, Julien; Flaig, Amandine; Grenier-Boley, Benjamin et al. (2017) Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. Acta Neuropathol 133:955-966|
|Lee, Edward B; Porta, Sílvia; Michael Baer, G et al. (2017) Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol 134:65-78|
|Monsell, Sarah E; Mock, Charles; Fardo, David W et al. (2017) Genetic Comparison of Symptomatic and Asymptomatic Persons With Alzheimer Disease Neuropathology. Alzheimer Dis Assoc Disord 31:232-238|
|Sims, Rebecca (see original citation for additional authors) (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49:1373-1384|
Showing the most recent 10 out of 586 publications